The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Original Article
Decreased Maternal Weight Gain in Pregnancy Is Seen with Buprenorphine Medication-Assisted Treatment
Abstract
Objectives: Medication-assisted treatment (MAT) is associated with low maternal weight gain, and low maternal weight gain is associated with infant mortality. Many MAT patients also are smokers. This study investigates buprenorphine administration during pregnancy as a possible independent risk factor for low maternal weight gain. To our knowledge, this is the first study that compares pregnant buprenorphine patients with both smoking and nonsmoking pregnant control groups.Methods: Our institution offers a combined MAT and prenatal care program for pregnant patients with opioid use disorder. With institutional review board approval, we retrospectively studied four groups of pregnant patients: very-low-dose (University) MAT, 83 patients; standard dose (community) MAT, 77 patients; smokers not taking MAT, 75 patients; and nonsmokers also not taking MAT, 167 patients. Informed consent was waived by the institutional review board, and standard methods were employed to maintain confidentiality. Exclusion criteria were body mass index greater than 30 at onset of care or inability to document body mass index, preterm delivery, incomplete data, intrauterine fetal demise or fetal anomaly, late prenatal care, polysubstance use, and maternal medical comorbidities.
Results: An analysis of variance of 402 patients showed that women using buprenorphine gained less weight than women not using buprenorphine (P = 0.021). Although the very-low-dose group gained more weight (average 24.92 lb) compared with the standard-dose group (average 21.34 lb), the difference was not significant. The difference between the very-low-dose buprenorphine group and the nonsmoking, nonbuprenorphine group, as well as between the standard-dose buprenorphine group and the nonsmoking, non-buprenorphine group also were statistically significant.
Conclusions: Buprenorphine MAT may be an independent risk factor for decreased maternal weight gain. Given this association of maternal MAT with low birth weight, further research could explore potential advantages of nutritional supplementation for pregnant patients undergoing MAT at risk for the delivery of low-birth-weight infants.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Davis J, Heiselman C, Staszewski C, et al. Opioid maintenance therapy (OMT) outcomes on maternal weight gain [24E]. Obstet Gynecol 2020;135:56S–56S.
2. Alexander C, Olsen M. A comparison of BMI and drug screens among pregnant patients at an Appalachian clinic. Am J Obstet Gynecol 2020;222:S635–S636.
3. Tomedi LE, Bogen DL, Hanusa BH, et al. A pilot study of the nutritional status of opiate-using pregnant women on methadone maintenance therapy. Subst Use Misuse 2012;47:286–295.
4. Marshall NE, Abrams B, Barbour LA, et al. The importance of nutrition in pregnancy and lactation: lifelong consequences. Am J Obstet Gynecol 2022;226:607–632.
5. Goldstein RF, Abell SK, Ranasinha S, et al. Association of gestational weight gain with maternal and infant outcomes: a systematic review and meta-analysis. JAMA 2017;317:2207.
6. Han Z, Lutsiv O, Mulla S, et al. Low gestational weight gain and the risk of preterm birth and low birthweight: a systematic review and meta-analyses. Acta Obstet Gynecol Scand 2011;90: 935–954.
7. Hannaford K, Tuuli M, Odibo L, et al. Gestational weight gain: association with adverse pregnancy outcomes. Am J Perinatol 2016;34:147–154.
8. Wei X, Shen S, Huang P, et al. Gestational weight gain rates in the first and second trimesters are associated with small for gestational age among underweight women: a prospective birth cohort study. BMC Pregnancy Childbirth 2022;22:106.
9. Davis RR, Hofferth SL. The association between inadequate gestational weight gain and infant mortality among U.S. infants born in 2002. Matern Child Health J 2012;16:119–124.
10. Pugh SJ, Albert PS, Kim S, et al. Patterns of gestational weight gain and birthweight outcomes in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies–Singletons: a prospective study. Am J Obstet Gynecol 2017;217:346. e1–346.e11.
11. Hall SM, Humfleet GL, Gasper JJ, et al. Cigarette smoking cessation intervention for buprenorphine treatment patients. Nicotine Tob Res 2018;20:628–635.
12. Kelty E, Havard A, Preen DB. Trends in smoking during pregnancy stratified by the use of opioid agonist therapy and the contribution of smoking to poor outcome in neonates prenatally exposed to opioid agonist treatment. Arch Womens Ment Health 2023;26:543–548.
13. Chisolm MS, Fitzsimons H, Leoutsakos JMS, et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tob Res 2013;15:1297–1304.
14. Davis RR, Hofferth SL, Shenassa ED. Gestational weight gain and risk of infant death in the United States. Am J Public Health 2014;104(S1):S90–S95.
15. Shah D, Chroust A, Olsen M. Does weaning of buprenorphine in pregnancy (in outpatient setting) improve neonatal and maternal outcome?. Obstet Gynecol 2023;141(5S):4S–5S.
16. Shrestha S, Jimenez E, Garrison L, et al. Dietary intake among opioid- and alcohol-using pregnant women. Subst Use Misuse 2018;53:260–269.
17. Rasmussen KM, Catalano PM, Yaktine AL. New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. Curr Opin Obstet Gynecol 2009;21: 521–526.
18. Sridhar SB, Xu F, Hedderson MM. Trimester-specific gestational weight gain and infant size for gestational age. PLOS ONE 2016;11:e0159500.
19. Grant LP, Haughton B, Sachan DS. Nutrition education is positively associated with substance abuse treatment program outcomes. J Am Diet Assoc 2004;104:604–610.
20. Rasmussen KM, Yaktine AL, eds., Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press; 2009.
21. ACOG Committee on Obstetric Practice. Committee opinion no. 548: weight gain during pregnancy. Obstet Gynecol 2013;121:210–212.
22. Nagarajan MK, Goodman D. Not just substance use: the critical gap in nutritional interventions for pregnant women with opioid use disorders. Public Health 2020;180: 114–116.
23. Pac J, Durrance C, Berger L, et al. The effects of opioid use during pregnancy on infant health and well-being. Ann Am Acad Pol Soc Sci 2022;703:106–138.
24. Schlienz NJ, Huhn AS, Speed TJ, et al. Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. Int Rev Psychiatry 2018;30:147–154.
25. Manza P, Kroll D, McPherson KL, et al. Sex differences in weight gain during medication-based treatment for opioid use disorder: a meta-analysis and retrospective analysis of clinical trial data. Drug Alcohol Depend 2022;238:109575.
26. Sadek GE, Chiu S, Cernovsky ZZ. Body composition changes associated with methadone treatment. Int J High Risk Behav Addict 2016;5:e27587.
27. Baykara S, Alban K. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Psychiatry Res 2019;272: 450–453.
28. Staszewski CL, Garretto D, Garry ET, et al. Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. J Perinat Med 2020; 48:677–680.
29. Kanervo MM, Tupola SJ, Nikkola EM, et al. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstet Gynecol Scand 2023;102:313–322.
30. Kinsella M, Halliday LOE, Shaw M, et al. Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis. Subst Use Misuse 2022;57:1400–1416.
31. McGlothen-Bell K, Cleveland L, Recto P, et al. Feeding behaviors in infants with prenatal opioid exposure: an integrative review. Adv Neonatal Care 2020;20:374–383.
32. Huang L, Jiang S, Xu J, et al. Associations between prepregnancy body mass index, gestational weight gain and weight catch-up in small-for-gestational-age children. Matern Child Nutr 2022;18:e13235.
